MA34658B1 - Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine - Google Patents

Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine

Info

Publication number
MA34658B1
MA34658B1 MA35892A MA35892A MA34658B1 MA 34658 B1 MA34658 B1 MA 34658B1 MA 35892 A MA35892 A MA 35892A MA 35892 A MA35892 A MA 35892A MA 34658 B1 MA34658 B1 MA 34658B1
Authority
MA
Morocco
Prior art keywords
group
atom
cellarized
linear
derivatives
Prior art date
Application number
MA35892A
Other languages
English (en)
Inventor
Elisabeth Dupont-Passelaigue
Roy Isabelle Le
Christophe Pignier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA34658B1 publication Critical patent/MA34658B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES DÉRIVÉS D'HÉTÉROARYLSULFONAMIDES, NOTAMMENT COMME BLOQUEURS DES CANAUX POTASSIQUES KV, ET PLUS PARTICULIÈREMENT DES CANAUX KV1.5, KV4.3 OU KV11.1, SUR LEUR APPLICATION EN THÉRAPIE CLINIQUE ET SUR LEURS PROCÉDÉS DE PRÉPARATION. CES COMPOSÉS CORRESPONDENT À LA FORMULE GÉNÉRALE (I) SUIVANTE : DANS LAQUELLE R1 REPRÉSENTE UN OU PLUSIEURS SUBSTITUANTS DU NOYAU PHÉNYLE X TELS QUE : L'ATOME D'HYDROGÈNE, UN ATOME D'HALOGÈNE, LE GROUPE TRIFLUOROMÉTHYLE, LE GROUPE TRIFLUOROMÉTHOXY, UN GROUPE ALKYLE EN C1-C4 LINÉAIRE OU RAMIFIÉ OU UN GROUPE ALCOXY EN C1-C4 LINÉAIRE OU RAMIFIÉ, A REPRÉSENTE L'ATOME D'OXYGÈNE OU L'ATOME DE SOUFRE, B REPRÉSENTE L'ATOME D'AZOTE LORSQUE N = 1 OU 2 ET D REPRÉSENTE -C(=O)-, OU B REPRÉSENTE CH LORSQUE N = 0 ET D REPRÉSENTE -CH2O- OU LORSQUE N = 1 ET D REPRÉSENTE -O-, R2 REPRÉSENTE L'ATOME D'HYDROGÈNE, LE GROUPE MÉTHYLE, L'ATOME DE FLUOR OU L'ATOME DE CHLORE OU LE GROUPE MÉTHOXY, HETAR REPRÉSENTE LE GROUPE PYRIDYLE OU QUINOLYLE, ÉVENTUELLEMENT SUBSTITUÉ PAR UN GROUPE TEL QU'UN GROUPE ALKYLE EN C1-C4 LINÉAIRE OU RAMIFIÉ, UN GROUPE ALCOXY EN C1-C4 LINÉAIRE OU RAMIFIÉ, UN ATOME D'HALOGÈNE OU LE GROUPE TRIFLUOROMÉTHYLE. L'INVENTION PORTE ÉGALEMENT SUR LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES.
MA35892A 2010-11-23 2013-05-13 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine MA34658B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
PCT/EP2011/070736 WO2012069503A1 (fr) 2010-11-23 2011-11-23 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine

Publications (1)

Publication Number Publication Date
MA34658B1 true MA34658B1 (fr) 2013-11-02

Family

ID=44246390

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35892A MA34658B1 (fr) 2010-11-23 2013-05-13 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine

Country Status (20)

Country Link
US (2) US8846930B2 (fr)
EP (1) EP2643318A1 (fr)
JP (1) JP5837085B2 (fr)
KR (1) KR101838326B1 (fr)
CN (1) CN103209980B (fr)
AR (1) AR083903A1 (fr)
AU (1) AU2011333772B2 (fr)
BR (1) BR112013012615A2 (fr)
CA (1) CA2817531A1 (fr)
FR (1) FR2967674B1 (fr)
HK (1) HK1187345A1 (fr)
IL (1) IL226495A (fr)
MA (1) MA34658B1 (fr)
MX (1) MX352396B (fr)
MY (1) MY168283A (fr)
NZ (1) NZ610700A (fr)
RU (1) RU2582995C2 (fr)
TW (1) TWI576106B (fr)
UA (1) UA109295C2 (fr)
WO (1) WO2012069503A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101712035B1 (ko) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
SG194697A1 (en) * 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CA2834692A1 (fr) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Activateurs de la pyruvate kinase destines a une utilisation therapeutique
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
CN105705495A (zh) * 2013-10-17 2016-06-22 巴斯夫欧洲公司 制备取代靛红酸酐化合物及其衍生物的方法
WO2015095111A1 (fr) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Antagonistes de récepteur d'orexine à base de diazépane
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique
EP4344703A1 (fr) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
JP2020511511A (ja) * 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
CN113200934B (zh) * 2021-05-18 2022-05-31 郑州大学 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用
CN113912595B (zh) * 2021-10-12 2024-03-15 中国药科大学 一类含有噻唑或噻二唑结构的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149700A (en) * 1990-05-30 1992-09-22 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
AU2005313581B2 (en) * 2004-12-09 2011-06-09 F. Hoffmann-La Roche Ag Phenyl-piperazin methanone derivatives
AU2006255465A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2006282403B2 (en) * 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
EP2215080A1 (fr) * 2007-10-25 2010-08-11 Boehringer Ingelheim International GmbH Composés de diazépane qui modulent le récepteur cb2
EP2303850A4 (fr) * 2008-06-13 2012-10-31 Bionomics Ltd Nouveaux bloqueurs du canal potassique et leurs utilisations
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN101503392B (zh) * 2009-03-31 2010-12-29 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途
WO2010130638A1 (fr) * 2009-05-14 2010-11-18 Evotec Ag Composés sulfamides, compositions pharmaceutiques et leurs utilisations
KR101712035B1 (ko) * 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물

Also Published As

Publication number Publication date
JP5837085B2 (ja) 2015-12-24
RU2582995C2 (ru) 2016-04-27
IL226495A0 (en) 2013-07-31
IL226495A (en) 2017-06-29
AU2011333772A1 (en) 2013-06-06
CA2817531A1 (fr) 2012-05-31
FR2967674A1 (fr) 2012-05-25
AU2011333772B2 (en) 2016-08-18
CN103209980A (zh) 2013-07-17
FR2967674B1 (fr) 2012-12-14
AR083903A1 (es) 2013-04-10
BR112013012615A2 (pt) 2016-09-06
JP2014502268A (ja) 2014-01-30
CN103209980B (zh) 2015-06-03
KR20130119943A (ko) 2013-11-01
HK1187345A1 (en) 2014-04-04
MX352396B (es) 2017-11-22
TWI576106B (zh) 2017-04-01
US8846930B2 (en) 2014-09-30
RU2013126251A (ru) 2014-12-27
UA109295C2 (uk) 2015-08-10
WO2012069503A1 (fr) 2012-05-31
MY168283A (en) 2018-10-19
MX2013005734A (es) 2013-08-01
KR101838326B1 (ko) 2018-03-13
NZ610700A (en) 2014-12-24
US20140357624A1 (en) 2014-12-04
US9156834B2 (en) 2015-10-13
EP2643318A1 (fr) 2013-10-02
US20130172326A1 (en) 2013-07-04
TW201225951A (en) 2012-07-01

Similar Documents

Publication Publication Date Title
MA34658B1 (fr) Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine
MA26996A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TW200602043A (en) Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
SE0104334D0 (sv) Therapeutic agents
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
DK1539700T3 (da) 8-hydroxyquinolin-derivater
EA200700103A1 (ru) НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
MA30695B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole -2-carboxamides, leur preparation et leur application en therapeutique.
IN2014CN00532A (fr)
HUP9700574A2 (hu) N,N-Dimetil-(3-fenil-but-3-én)-amin-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
DK1653943T3 (da) Catecholderivater til behandling af cancer
EE200000504A (et) Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to
MA31832B1 (fr) Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques
RU2012155118A (ru) Способы лечения биполярного расстройства
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
NI200400073A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
MA28211A1 (fr) Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent